Technical Analysis

Analyst(s)

Greater China Research Team
research-hk@uobkh.com

Tham Mun Hon, CFA
munhon.tham@uobkh.com
+852 2236 6799



CITIC (0267 HK)

Last price:	HK$12.94
Support levels:	HK$12.49/HK$12.10
Resistance levels:	HK$13.70/HK$14.57

Price successfully defended its position above the gap-support baseline and formed a flag continuation pattern. The RSI is in bullish territory and continues to slope upward with positive velocity. An upward breakout wave targeting the upper swing high resistance boundaries can be expected once price breaks out of the flag pattern.

Average timeframe: Around two weeks.



Innovent Biologics (1801 HK)

Last price:	HK$86.80
Support levels:	HK$84.40/HK$77.90
Resistance levels:	HK$98.95/HK$103.50

Price successfully maintained its position above the gap-support baseline on intraday retests. It is compressing within a tight range. The RSI is hovering around the 50 neutral baseline. As long as price remains defended above the gap-support baseline, we see an upward expansion wave targeting the upper swing high resistance.

Average timeframe: Around two weeks.

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at this link or by scanning the QR code below:

The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."